Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Experimental Neurology

• Publication date

  2013-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.expneurol.2013.07.006PMID 23876516
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies.

  2013cited by this paper
• Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.

  2012cited by this paper
• Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

  2011cited by this paper
• Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice

  2011cited by this paper
• Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models

  2011cited by this paper
• A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE

  2010cited by this paper
• Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model

  2010cited by this paper
• Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice.

  2010influential reference
• Mild experimental autoimmune encephalitis as a tool to induce blood–brain barrier dysfunction

  2010influential reference
• A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

  2009cited by this paper
• A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.

  2008cited by this paper
• Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements

  2007influential reference
• Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein.

  2006influential reference
• Aβ-induced meningoencephalitis is IFN-γ-dependent and is associated with T cell-dependent clearance of Aβ in a mouse model of Alzheimer's disease

  2006cited by this paper
• Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease.

  2006cited by this paper
• Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

  2005cited by this paper
• Are the Extracellular Pathways a Conduit for the Delivery of Therapeutics to the Brain

  2004cited by this paper
• Are the extracellular [correction of extracelluar] pathways a conduit for the delivery of therapeutics to the brain?

  2004cited by this paper
• Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice.

  2003cited by this paper
• Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

  2003cited by this paper
• The central nervous sytem-specific myelin oligodendrocytic basic protein (MOBP) is encephalitogenic and a potential target antigen in multiple sclerosis (MS)

  2000cited by this paper
• Uptake of antineuronal IgM by CNS neurons

  1990cited by this paper
• Reduced humoral immune activity in long-lived old mice: an approach to elucidating its mechanisms.

  1976cited by this paper

• Tau protein: Physiological functions and multifaceted roles in neurodegenerative and psychiatric disorders.

  2025cites this paper
• Tau-targeting active immunotherapy slows progression and reduces pathology in mouse models of tauopathy.

  2025cites this paper
• Dual Aβ/tau epitope vaccines: a poorly explored strategy for Alzheimer's disease immunotherapy.

  2025cites this paper
• Tau-Targeted Immunotherapy for Alzheimer's Disease: Insight into Clinical Trials

  2024cites this paper
• The neuroinflammatory role of microRNAs in Alzheimer’s disease: pathological insights to therapeutic potential

  2024cites this paper
• Role of neuroinflammation in neurodegeneration development

  2023cites this paper
• Tau-targeting therapies for Alzheimer disease: current status and future directions

  2023cites this paper
• Research progress of the CXCR4 mechanism in Alzheimer's disease

  2022cites this paper
• Investigational therapeutics for the treatment of progressive supranuclear palsy

  2022cites this paper
• Active immunotherapy against pathogenic Cis pT231-tau suppresses neurodegeneration in traumatic brain injury mouse models.

  2022cites this paper
• TNAP upregulation is a critical factor in Tauopathies and its blockade ameliorates neurotoxicity and increases life-expectancy.

  2022cites this paper
• Targeting tau only extracellularly is likely to be less efficacious than targeting it both intra- and extracellularly.

  2021cites this paper
• P2 × 7 receptor blockade reduces Tau induced toxicity, therapeutic implications in Tauopathies.

  2021cites this paper
• Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology.

  2020cites this paper
• Genetic factors related to the immune system in subjects at risk of developing Alzheimer's disease.

  2020cites this paper
• Intravenous Injection of PHF-Tau Proteins From Alzheimer Brain Exacerbates Neuroinflammation, Amyloid Beta, and Tau Pathologies in 5XFAD Transgenic Mice

  2020cites this paper
• Progressive supranuclear palsy: Advances in diagnosis and management.

  2020cites this paper
• Passive immunotherapy for N-truncated tau ameliorates the cognitive deficits in two mouse Alzheimer’s disease models

  2020cites this paper
• Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice

  2020cites this paper
• Qß Virus-like particle-based vaccine induces robust immunity and protects against tauopathy

  2019cites this paper
• Intersection of pathological tau and microglia at the synapse

  2019cites this paper
• Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls

  2018cites this paper
• Prospects for strain-specific immunotherapy in Alzheimer’s disease and tauopathies

  2018cites this paper
• Prévention du phénomène de nucléation et de la propagation des tauopathies par immunothérapie passive utilisant un anticorps ciblant une région centrale de la protéine tau

  2018cites this paper
• Phos‐tau peptide immunization of amyloid‐tg‐mice reduced non‐mutant phos‐tau pathology, improved cognition and reduced amyloid plaques

  2018influential citation
• Tau-targeting therapies for Alzheimer disease

  2018cites this paper
• Tau-based therapies in neurodegeneration: opportunities and challenges

  2017cites this paper
• Tau-Directed Immunotherapy for Alzheimer's Disease

  2017cites this paper
• Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-β Pathologies in 3xTg Mice

  2017cites this paper
• Emerging Diagnostic and Therapeutic Strategies for Tauopathies

  2017cites this paper
• Vaccination strategies in tauopathies and synucleinopathies

  2017cites this paper
• Preclinical models of Alzheimer’s disease for identification and preclinical validation of therapeutic targets: from fine-tuning strategies for validated targets to new venues for therapy

  2017cites this paper
• MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice.

  2017cites this paper
• Vaccination to Alzheimer Disease. Is it a Promising Tool or a Blind Way?

  2016cites this paper
• Therapeutic Approaches Targeting Pathological Tau Aggregates.

  2016cites this paper
• Therapeutic strategies for the treatment of tauopathies: Hopes and challenges

  2016cites this paper
• Tau physiology and pathomechanisms in frontotemporal lobar degeneration

  2016cites this paper
• Pharmacological Effects of Active Components of Chinese Herbal Medicine in the Treatment of Alzheimer's Disease: A Review.

  2016cites this paper
• Physiological functions and pathobiology of TDP‐43 and FUS/TLS proteins

  2016cites this paper
• A retrospective analysis of the Alzheimer's disease vaccine progress – The critical need for new development strategies

  2016influential citation
• Tau neurotoxicity and rescue in animal models of human Tauopathies.

  2016cites this paper
• Novel Therapeutic Strategies for Dementia.

  2016cites this paper
• Studying the Interactions Between Tau, Amyloid, and α-Synuclein in Alzheimer’s Disease Animal and Human Cell Models

  2016cites this paper
• Tau immunization: a cautionary tale?

  2015cites this paper
• Prévenir la progression de la pathologie Tau par immunothérapie passive

  2015cites this paper
• Tau Immunotherapy

  2015cites this paper
• Further understanding of tau phosphorylation: implications for therapy

  2015cites this paper
• Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer’s Disease and Other Tauopathies

  2015cites this paper
• Immunotherapeutic approaches for Alzheimer's disease.

  2015cites this paper
• Tau Immunotherapy Modulates Both Pathological Tau and Upstream Amyloid Pathology in an Alzheimer's Disease Mouse Model

  2015cites this paper
• Alzheimer's disease vaccine development: A new strategy focusing on immune modulation.

  2015cites this paper
• [Passive Tau immunotherapy for prevention of Tau pathology progression].

  2015cites this paper
• Neuroinflammation in Alzheimer’s disease

  2015cites this paper
• Tau‐targeting passive immunization modulates aspects of pathology in tau transgenic mice

  2015cites this paper
• Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice

  2015cites this paper
• Protein phosphorylation in neurodegeneration: friend or foe?

  2014cites this paper
• Novel immunological approaches for the treatment of Alzheimer's disease.

  2014cites this paper
• Pharmacogenomics in Drug Discovery and Development

  2014cites this paper
• Should development of Alzheimer’s disease-specific intravenous immunoglobulin be considered?

  2014cites this paper
• Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-Modifying Drugs. Update 2014

  2014cites this paper
• Pharmacogenomics of Alzheimer's disease: novel therapeutic strategies for drug development.

  2014cites this paper
• Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

  2014cites this paper
• Amyloid beta peptide immunotherapy in Alzheimer disease.

  2014cites this paper
• Biotherapies in neurological diseases Amyloid beta peptide immunotherapy in Alzheimer disease Immunothérapie anti-amyloı̈de dans la maladie d ’ Alzheimer

  2014cites this paper
• Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species.

  2014cites this paper
• Immunotherapy for Alzheimer's disease.

  2014cites this paper
• Vaccination with Sarkosyl Insoluble PHF-Tau Decrease Neurofibrillary Tangles Formation in Aged Tau Transgenic Mouse Model: A Pilot Study

  2014cites this paper
• Harnessing the Immune System for Treatment and Detection of Tau Pathology

  2014cites this paper
• Alzheimer's disease: is a vaccine possible?

  2014cites this paper
• Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer’s Disease Like Tau Aggregation

  2014influential citation
• Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

  2013cites this paper
• Running head : ALZHEIMER ’ S PATHOGENESIS AND TREATMENTS 1 Alzheimer ’ s Disease : Risk Factors , Pathogenesis and Treatments

  year unknowncites this paper